Repertoire Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE:BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Under the terms of the agreement, Repertoire will receive an upfront payment of $65 million, and up to $1.8 billion for achieving development, regulatory and commercial milestones in addition to receiving tiered royalties.